Recent 8-K filings for GENB
Highest-materiality recent filing
Generate:Biomedicines reveals GB-0895 data: ~98-day half-life, 6-month biomarker control
- Phase 1 (GB-0895-101): single 300 mg SC cuts BEC, FeNO, IL-5, IL-13 in mild-moderate asthma for ≥6 months; ~98-day half-life.
- COPD Part C (N=40): biomarker reductions from Month 1 sustained ≥6 months; 300 mg comparable to 600 mg; no related SAEs.
-
Generate:Biomedicines reveals GB-0895 data: ~98-day half-life, 6-month biomarker control
Phase 1 (GB-0895-101): single 300 mg SC cuts BEC, FeNO, IL-5, IL-13 in mild-moderate asthma for ≥6 months; ~98-day half-life.
-
Generate Biomedicines Q2 net loss $67.3M; Phase 3 asthma studies advancing, cash $457.4M
Revenue $6.3M (down from $10.1M YoY); net loss $67.3M vs $56.7M YoY; cash $457.4M (down from $516.6M Q1).
-
Generate Q1 net loss widens to $61.7M, cash $516.6M post-IPO; pipeline advances
Net loss $61.7M vs $44.3M YoY; revenue $7.2M (down 18% from $8.8M).
-
Generate Biomedicines adopts amended charter and bylaws for public company governance
Amended charter authorizes 500M common shares and 10M undesignated preferred shares.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.60 · Most common event earnings